Trabectedin for the management of soft-tissue sarcoma

Area of Science:

• Marine pharmacology
• Molecular oncology
• DNA repair mechanisms

Background:

• Trabectedin is a novel marine-derived compound with a unique mechanism of action.
• It interacts with the DNA minor groove and DNA repair proteins.
• Previous studies indicated promising single-agent activity in specific cancers.

Purpose of the Study:

• To review the efficacy and toxicity of trabectedin.
• To discuss its regulatory approval and current research directions.
• To highlight its role in treating advanced cancers.

Main Methods:

• Review of preclinical and clinical data on trabectedin.
• Analysis of safety profiles, including hematological and hepatic toxicities.
• Examination of regulatory approvals and ongoing research.

Main Results:

• Trabectedin demonstrates single-agent activity in pretreated soft-tissue sarcoma (STS), ovarian, and breast cancer patients.
• Combination therapy with other chemotherapeutics is feasible.
• Common toxicities include grade 3-4 neutropenia (approx. 50%), thrombocytopenia (approx. 20%), and elevated liver transaminases (35-50%).

Conclusions:

• Trabectedin is approved for STS treatment post-failure of standard chemotherapy.
• Ongoing research focuses on predictive factor identification and novel combination therapies.
• Trabectedin represents a valuable therapeutic option for specific advanced cancers.